Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Spruce Biosciences, Inc. (SPRB) PT Lowered to $4 at Oppenheimer
March 14, 2024 9:11 AM EDTOppenheimer analyst Hartaj Singh lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $4.00 (from $7.00) while maintaining a Outperform rating.
The analyst comments "Spruce (SPRB) announced top-line results from the CAHmelia-203 and CAHptain-205 studies of tildacerfont in adult and pediatric classic CAH,... More
